An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2015
At a glance
- Drugs Buparlisib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Therapeutic Use
- 16 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 24 Jan 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 19 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.